1. Signaling Pathways
  2. Epigenetics
  3. Histone Methyltransferase

Histone Methyltransferase

Methyltransferase

Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.

DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.

Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me3), leading to chromatin condensation and transcriptional repression.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114206
    SKI-73
    SKI-73 is a chemical probe for CARM1 with prodrug properties. SKI-73 can rapidly penetrate cell membranes and be processed into active inhibitors. SKI-73 inhibits the invasion of breast cancer cells and can be used in the study of cancer.
    SKI-73
  • HY-100235A
    GSK591 hydrochloride
    Inhibitor
    GSK591 (EPZ015866) hydrochloride is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM.
    GSK591 hydrochloride
  • HY-122115
    DCE_42
    Inhibitor
    DCE_42 is a potent EZH2 inhibitor with an IC50 value of 22.6 µM. DCE_42 inhibits cell proliferation and has the potential for the research of lymphoma.
    DCE_42
  • HY-122532
    Fagaronine chloride
    Fagaronine chloride is an alkaloid with inhibitory activity against reverse transcriptase and topoisomerase I. Fagaronine chloride can effectively inhibit the reverse transcriptase of RSii tumor virus at a concentration of 6-60 μg/mL. Fagaronine chloride rapidly blocks the synthesis of DNA polymerase by interacting with the template primer. Fagaronine chloride has shown anti-tumor potential, especially in the study of retroviral infection.
    Fagaronine chloride
  • HY-12707R
    Piribedil (Standard)
    Inhibitor
    Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers.
    Piribedil (Standard)
  • HY-110093
    UNC0638 hydrate
    Inhibitor
    UNC0638 hydrate selectively inhibits G9a and GLP histone methyltransferases with IC50 of 15 nM and 19 nM, respectively. UNC0638 hydrate inhibits TNBC cell invasion and migration in vitro. UNC0638 hydrate is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 hydrate has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets.
    UNC0638 hydrate
  • HY-172369
    CARM1/IKZF3 ligand 1
    Inhibitor
    CARM1/IKZF3 ligand 1 is the inhibitor for CARM1 that can be used as the target protein ligand for synthesis of PROTAC CARM1/IKZF3 degrader-1 (HY-172368).
    CARM1/IKZF3 ligand 1
  • HY-P10463
    ssK36
    Inhibitor
    ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. It is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency.
    ssK36
  • HY-117583A
    BG47
    Activator
    BG47 is a prototypical histone deacetylases HDAC1 and HDAC2 selective, optoepigenetic probe. BG47 can bind to and competitively inhibits the deacetylase activity of HDAC targets upon a light-induced trans-to-cis isomerization, and increases Histone Methyltransferase H3K9 acetylation. BG47 can be used for neurological disease research.
    BG47
  • HY-111030
    PRMT1-IN-2
    Inhibitor
    PRMT1-IN-2 (RM65) is a potent PRMT1 inhibitor with an IC50 of 55.4 μM. PRMT1-IN-2 shows histone hypomethylation in HepG2 cells.
    PRMT1-IN-2
  • HY-116255
    MS453
    MS453 is a potent and highly selective SETD8 inhibitor with an IC50 value of 804 nM. MS453 specifically modifies a cysteine residue close to the inhibitor binding site. MS453 is selective for 28 other methyltransferases. The crystal structure of MS453 reveals its binding mode to SETD8, providing an atomic-level view for the development of high-quality chemical probes for SETD8.
    MS453
  • HY-125655
    UNC-4219 TFA
    Control
    UNC-4219 TFA is a negative control for the CBX7-H3 antagonist UNC3866 (HY-100832) and does not interact with CBX7 at high concentrations.
    UNC-4219 TFA
  • HY-W013500
    (1-Nitroethene-1,2-diyl)dibenzene
    Inhibitor
    (1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) is an inhibitor of protein arginine methyltransferase 1 (PRMT1; IC50=11 μM in histone H4 methylation assay). It also inhibits histone H4 methylation by PRMT8, but not histone H3.1 methylation by CARM1 or Set7/9, at concentrations of 10 and 100 μM.
    (1-Nitroethene-1,2-diyl)dibenzene
  • HY-122223
    EPZ030456
    Inhibitor
    EPZ030456 is a potent and selective SMYD3 inhibitor with an IC50 of 48 nM. EPZ030456 can be used for cancer research.
    EPZ030456
  • HY-164500
    MC3629
    Inhibitor
    MC3629 is an inhibitor of histone methyltransferase (EZH2) with anti-tumor activity. MC3629 inhibits SHH MB cancer cell proliferation and self-renewal and induces apoptosis. MC3629 can be used to study drug resistance in tumor aggressiveness.
    MC3629
  • HY-168164
    4-Methoxycinnamyl alcohol
    4-Methoxycinnamyl alcohol is an anticancer compound with cytotoxic activity against MCF-7, HeLa, and DU145 cancer cell lines with IC50 values of 14.24, 7.82, and 22.10 μg/mL, respectively. 4-Methoxycinnamyl alcohol showed the ability to induce cell necrosis, rather than apoptosis, after a 48-hour DNA fragmentation assay. 4-Methoxycinnamyl alcohol was isolated from Foeniculum vulgare.
    4-Methoxycinnamyl alcohol
  • HY-19546A
    (R)-BAY-598
    Inhibitor
    (R)-BAY-598 ((R)-4) is a potent inhibitor of protein-lysine methyltransferase SMYD2, with the IC50 of 1.7 μM.
    (R)-BAY-598
  • HY-164479
    GA001
    Antagonist
    GA001 is a potent G9a antagonist, with an IC50 of 1.32 μM. GA001 induces autophagy and apoptosis that can be used for the breast cancer.
    GA001
  • HY-169113
    EPZ032597
    Inhibitor
    EPZ032597 is a selective and noncompetitive SMYD2 inhibitor with an IC50 value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma.
    EPZ032597
  • HY-B1377
    Acedapsone
    Acedapsone is a compound with antimalarial and antimicrobial activities. Acedapsone is mainly used as a long-acting leprosy inhibitor.
    Acedapsone
Cat. No. Product Name / Synonyms Application Reactivity

EZH1

EZH2

DOT1L

SMYD2

SMYD3

SUV39H2/KMT1B

EHMT2/G9a/KMT1C

EHMT1/GLP/KMT1D

ASH1L/KMT2H

SETDB1/KMT2G

SETD2/KMT3A

NSD2/MMSET/WHSC1

SETD7/KMT7

SETD8/KMT5A

PRMT1

PRMT3

PRMT4

PRMT5

PRMT6

PRMT7

PRMT8

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Histone Methyltransferase Degraders & Inhibitors
Product NameEZH1EZH2DOT1LSMYD2SMYD3SUV39H2/KMT1BEHMT2/G9a/KMT1CEHMT1/GLP/KMT1DASH1L/KMT2HSETDB1/KMT2GSETD2/KMT3ANSD2/MMSET/WHSC1SETD7/KMT7SETD8/KMT5APRMT1PRMT3PRMT4PRMT5PRMT6PRMT7PRMT8Purity    
GSK126 
EZH2, IC50: 9.9 nM
                   99.98%
Tazemetostat 
EZH2
                   99.93%
Pinometostat  
DOT1L
                  99.99%
GSK3326595                 
PRMT5
   99.83%
3-Deazaneplanocin A hydrochloride 
EZH2
                   99.98%
NSD2-PWWP1-IN-1           
NSD2, IC50: 0.64 μM
         98.72%
NSD2-PWWP1-IN-3           
NSD2, IC50: 8.05 μM
         
NSD2-PWWP1-IN-2           
NSD2, IC50: 1.49 μM
         99.64%
GSK343 
EZH2
                   99.88%
BIX-01294      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             98.44%
EZM0414 TFA          
SETD2/KMT3A
          
Navlimetostat                 
PRMT5
   99.40%
GSK3368715 dihydrochloride              
PRMT1
PRMT3
PRMT4
 
PRMT6
 
PRMT8
99.96%
UNC0642      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             99.92%
EPZ015666                 
PRMT5
   99.83%
MS023              
PRMT1
PRMT3
  
PRMT6
 
PRMT8
99.73%
SGC0946  
DOT1L, IC50: .3 nM
                  99.68%
Onametostat                 
PRMT5
   99.79%
3-Deazaneplanocin A 
EZH2
                   99.97%
EPZ004777  
DOT1L
                  99.00%
UNC1999
EZH1
EZH2
                   99.87%
UNC0638      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             99.05%
Valemetostat
EZH1
                    99.84%
UNC0379             
SETD8/KMT5A
       99.90%
MS177 
EZH2
                   98.00%
GSK591                 
PRMT5
   99.91%
TP-064                
PRMT4, IC50: <10 nM
 
PRMT6, IC50: 1300 μM
  99.61%
SGC707               
PRMT3, IC50: 31 nM
     98.08%
A-366      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             98.01%
UNC0224      
G9a, IC50: 15 nM
G9a, Ki: 2.6 nM
G9a, Kd: 23 nM
EHMT1/GLP/KMT1D, IC50: 20-58 nM
             98.85%
EZM0414          
SETD2/KMT3A
          99.11%
SETDB1-TTD-IN-1         
SETDB1/KMT2G
           99.93%
MS1943 
EZH2 methyltransferase, IC50: 120 nM
                   98.92%
SGC3027                   
PRMT7
 98.06%
CM-272      
G9a, IC50: 8 nM
EHMT1/GLP/KMT1D, IC50: 2 nM
             98.70%
LLY-283                 
PRMT5
   99.22%
EPZ020411              
PRMT1, IC50: 0.119 μM
   
PRMT6, IC50: 0.01 μM
 
PRMT8, IC50: 0.223 μM
98.07%
A-395 
EZH2
                   99.12%
Ralometostat                 
PRMT5
   98.89%
PFI-2 hydrochloride            
SETD7/KMT7
        99.48%
AMI-1              
PRMT1
      ≥98.0%
Valemetostat tosylate
EZH1
                    99.84%
AS-99 TFA        
ASH1L/KMT2H
            99.15%
EPZ-719          
SETD2/KMT3A
          99.85%
AZ505   
SMYD2
                 99.99%
EPZ020411 hydrochloride              
PRMT1, IC50: 0.119 μM
   
PRMT6, IC50: 0.01 μM
 
PRMT8, IC50: 0.223 μM
98.15%
BCI-121    
SMYD3
                99.26%
LLY-507   
SMYD2, IC50: <15 nM
                 98.28%
UNC 0631      
G9a, IC50: 4 nM
              98.35%
EPZ031686    
SMYD3, IC50: 3 nM
                99.71%
EPZ011989 
EZH2
                   98.79%
PROTAC EZH2 Degrader-1 
EZH2, IC50: 2.7 nM
                   99.44%
UNC0321      
G9a, Ki: 63 pM
G9a, IC50: 6-9 nM
EHMT1/GLP/KMT1D, IC50: 15-23 nM
             99.91%
TC-E 5003              
PRMT1
      98.03%
Furamidine dihydrochloride              
PRMT1
      ≥99.0%
SGC2085                
PRMT4
    99.46%
PF-06939999                 
PRMT5
   99.84%
MS4322
EZH1
EZH2
DOT1L
SMYD2
SMYD3
SUV39H2/KMT1B
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
 
SETDB1/KMT2G
SETD2/KMT3A
NSD2
SETD7/KMT7
SETD8/KMT5A
PRMT1
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
99.14%
BVT948             
SETD8/KMT5A
       ≥99.0%
MS023 dihydrochloride              
PRMT1
PRMT3
  
PRMT6
 
PRMT8
99.30%
PF-06726304 
EZH2 WT, Ki: 0.7 nM
EZH2 Y641N, Ki: 3.0 nM
                   98.37%
BAY-598   
SMYD2
                 99.30%
EPZ005687 
EZH2, Ki: 24 nM
                   99.46%
MS117                  
PRMT6
  ≥98.0%
BRD4770      
EHMT2/G9a/KMT1C
              99.69%
Gambogenic acid 
EZH2
                   99.94%
JQEZ5 
EZH2
                   98.08%
C-7280948              
PRMT1
      98.57%
GSK503 
EZH2
                   99.52%
Dot1L-IN-4  
DOT1L, IC50: 0.11 nM
                  99.54%
RK-701      
G9a, IC50: 23-27 nM
              98.04%
CARM1-IN-1                
PRMT4
    
BAY-6035    
SMYD3, IC50: 88 nM
                99.82%
NUCC-0226272 
EZH2
                   99.68%
MRTX9768                 
PRMT5
   99.60%
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH 
EZH2
                   99.06%
Tulmimetostat
EZH1
EZH2
                   99.79%
MS049                
PRMT4, : 34 nM
 
PRMT6, : 43 nM
 
PRMT8, : 1600 nM
≥98.0%
GSK2807 Trifluoroacetate    
SMYD3, Ki: 14 nM
SMYD3, IC50: 130 nM
                99.36%
LLC0424           
NSD2, DC50: 20 nM
         98.42%
EI1 
EZH2 Y641F mutant type, IC50: 13 nM
EZH2 WT, EC50: 15 nM
                   99.78%
UNC0646      
G9a, IC50: 6 nM
GLP, IC50: <15 nM
             99.38%
OTS193320     
SUV39H2/KMT1B
               98.64%
EM127    
SMYD3
                98.37%
PRMT5-IN-25                 
PRMT5, Ki: 0.06 nM
   99.94%
AS-85        
ASH1L/KMT2H
            98.96%
DS-437                 
PRMT5
 
PRMT7
 98.00%
DCLX069              
PRMT1, IC50: 17.9 μM
      98.03%
HLCL-61 hydrochloride                 
PRMT5
   99.87%
AZ505 ditrifluoroacetate   
SMYD2
                 99.91%
EHMT2-IN-1      
EHMT2 PEP, IC50: <100 nM
EHMT2 ICW, IC50: <100 nM
EHMTI PEP, IC50: <100 nM
             99.85%
BRD0639                 
PRMT5
   98.04%
EHMT2-IN-2      
EHMT2 PEP, IC50: <100 nM
EHMT2 ICW, IC50: <100 nM
EHMTI PEP, IC50: <100 nM
             ≥99.0%
MS8847 
EZH2
                   99.78%
Navlimetostat hydrochloride                 
PRMT5
   99.22%
MS8511      
G9a, IC50: 100 nM
G9a, Kd: 44 nM
GLP, IC50: 140 nM
GLP, Kd: 46 nM
             
BRD9539      
G9a, IC50: 6.3 μM
              99.74%
SMYD3-IN-1    
SMYD3, IC50: 11.7 nM
                98.01%
EPIC-0628 
EZH2
                   98.93%
EZH2-IN-2 
EZH2, IC50: 64 nM
                   99.40%
CMP-5                 
PRMT5
   99.02%
Dot1L-IN-5  
DOT1L, IC50: 0.17 nM
                  99.82%
UNC2399 
EZH2, IC50: 17 nM
                   99.62%
MS4322 (isomer)
EZH1
EZH2
DOT1L
SMYD2
SMYD3
SUV39H2/KMT1B
EHMT2/G9a/KMT1C
EHMTI PEP
 
SETDB1/KMT2G
SETD2/KMT3A
NSD2
SETD7/KMT7
SETD8/KMT5A
PRMT1
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
99.22%
PR5-LL-CM01                 
PRMT5
   98.45%
EBI-2511 
EZH2
                   99.81%
GSK3368715              
PRMT1
PRMT3
PRMT4
 
PRMT6
 
PRMT8
99.24%
CARM1-IN-1 hydrochloride                
PRMT4
    
GNA002 
EZH2, IC50: 1.1 μM
                   98.02%
DC-S239  
DOT1L
   
EHMT2/G9a/KMT1C
              99.73%
SETDB1-TTD-IN-1 TFA         
SETDB1/KMT2G
           99.77%
Tanshindiol C 
EZH2, IC50: 0.55 μM
                   98.47%
NSC745885 
EZH2
                   ≥98.0%
ZZM-1220      
G9a, IC50: 458 nM
GLP, IC50: 924 nM
             98.74%
PRMT5-IN-30                 
PRMT5, IC50: 0.33 μM
PRMT5, Kd: 0.987 μM
   99.17%
EPZ011989 trifluoroacetate 
EZH2
                   98.71%
DW14800                 
PRMT5
   99.63%
CPUY074020      
EHMT2/G9a/KMT1C
              98.56%
Dot1L-IN-1 TFA  
DOT1L
                  98.56%
AZ506   
SMYD2, IC50: 17 nM
                 99.74%
SGC8158                   
PRMT7
 
YM458 
EZH2, IC50: 490 nM
                   99.16%
(S)-HH2853 
EZH2 Y641N, IC50: <100 nM
                   
A-893   
SMYD2
                 
PRMT5-IN-1                 
PRMT5
   
AS-99 free base        
ASH1L/KMT2H
            
EML741      
G9a, IC50: 23 nM
G9a, Kd: 1.13 μM
              
MRTX9768 hydrochloride                 
PRMT5
   99.88%
PRMT5-IN-1 hydrochloride                 
PRMT5
   99.50%
PRMT5-IN-4                 
PRMT5
   ≥99.0%
PFI-2            
SETD7/KMT7
        
TDI-6118 
EZH2
                   
(R)-HH2853 
EZH2 Y641F mutant type, IC50: <100 nM
                   
BIX-01294 hydrochloride hydrate      
G9a, IC50: 1.7 μM
GLP, IC50: 38 μM
             
CPI-1328 
EZH2
                   
AS-99        
ASH1L/KMT2H
            
Dot1L-IN-1  
DOT1L
                  
PRMT5-IN-14                 
PRMT5
   
GSK3368715 trihydrochloride              
PRMT1, IC50: 3.1 nM
PRMT3, IC50: 48 nM
PRMT4, IC50: 1148 nM
 
PRMT6, IC50: 5.8 nM
 
PRMT8, IC50: 1.7 nM
PF-06726304 acetate 
EZH2 WT, Ki: 0.7 nM
EZH2 Y641N, Ki: 3.0 nM
                   
3-Deazaneplanocin A hydrochloride (GMP) 
EZH2
                   
IHMT-EZH2-426 
EZH2 WT, IC50: 1.3 nM
EZH2-A687V, IC50: 1.2 nM
Y641F/Y641N/Y641S, IC50: 1.7-3.5 nM
                   
PRMT5-MTA-IN-1                 
PRMT5
   
PRMT5-IN-39-d3                 
PRMT5
   
EZH2-IN-22 
EZH2 Y641N, IC50: <0.00051 μM
EZH2 Y641F mutant type, IC50: <0.00051 μM
EZH2 WT, IC50: 0.00052 μM
                   
BBDDL2059 
EZH2 Y641F mutant type, IC50: 1.5 nM
                   
PRMT5-IN-34                 
PRMT5
   
EZH2-IN-4 
WT 5-mer EZH2, IC50: 0.923 nM
mut 5-mer EZH2, IC50: 2.65 nM
                   
EZH2/HSP90-IN-29 
EZH2, IC50: 6.29 nM
                   
EZH2-IN-16 
EZH2 WT, IC50: 37.6 nM
EZH2 Y641F mutant type, IC50: 79.1 nM
                   
Dot1L-IN-9  
DOT1L, IC50: 125 nM
                  
HDACs/EZH2-IN-1 
EZH2 WT, IC50: 0.84 nM
EZH2 Y641N, IC50: 1.36 nM
                   
PRMT5-IN-28                 
PRMT5
   
PRMT4-IN-1              
PRMT1, IC50: 0.835 μM
PRMT3, IC50: 4.05 μM
PRMT4, IC50: 3.2 nM
PRMT5, IC50: 1.46 μM
PRMT6, IC50: 1.75 μM
PRMT7, IC50: 1.68 μM
PRMT8, IC50: 1.95 μM
CSV0C018875      
G9a
              
DM-01 
EZH2
                   98.03%
PARP/EZH2-IN-2 
EZH2, IC50: 27.34 ± 1. nM
                   
PRMT5-IN-47                 
PRMT5, IC50: 15 nM
   
PRMT5-IN-19              
PRMT1, IC50: 3.252 μM
 
PRMT4, IC50: >20 μM
PRMT5, IC50: 23.9 nM
   
EZH2-IN-5 
EZH2 WT, IC50: 1.52 nM
EZH2 Y641F mutant type, IC50: 4.07 nM
                   
Antitumor agent-101      
G9a, IC50: 8.5 nM
GLP, IC50: 5.5 nM
             
SMYD3-IN-2    
SMYD3, IC50: 0.81 μM μM
                
CM112              
PRMT1
      
PARP/EZH2-IN-1 
EZH2, IC50: 36.51 nM
                   
PROTAC PRMT3 degrader 1               
PRMT3
     
W4275           
NSD2, IC50: 17 nM
         
(S)-Navlimetostat                 
PRMT5
   
PRMT5-IN-45                 
PRMT5, IC50: 3 nM
   
PRMT5-IN-43                 
PRMT5
   
PRMT3-IN-4               
PRMT3
     
PRMT5-IN-44                 
PRMT5
   
PRMT3-IN-5               
PRMT3, IC50: 261 nM
     
D-01 
EZH2, IC50: 0.99 μM
                   
PRMT5-IN-9                 
PRMT5, IC50: 0.01 μM
   
CARM1-IN-4              
PRMT1, IC50: 56 nM
PRMT3, IC50: 2637 nM
 
PRMT5, IC50: >100 (Pan)
PRMT6, IC50: 30 nM
 
PRMT8, IC50: 31 nM
Dot1L-IN-7  
DOT1L, IC50: 1 μM
                  
PRMT5-IN-23                 
PRMT5
   
UNC2327               
PRMT3
     99.70%
DCG066      
G9a
              99.78%
EZH2-IN-7 
EZH2
                   
AMI-408              
PRMT1
      
PRMT5-IN-49                 
PRMT5, IC50: > 100 μM
   
PRMT5-IN-33              
PRMT1, IC50: 6.89 μM
  
PRMT5, IC50: 10.9 nM
   
PRMT5-IN-21                 
PRMT5
   
PRMT5-IN-36-d3                 
PRMT5
   
EZH2-IN-19 
EZH2 WT, IC50: 0.32 nM
EZH2 Y641F mutant type, IC50: 0.03 nM
EZH2 Y641N, IC50: 0.08 nM
                   
MU1656  
DOT1L, IC50: 2 nM
                  
SGC2085 hydrochloride                  
PRMT6, IC50: 5.2 μM
  
EPZ0025654                  
PRMT6, IC50: 3 nM
  
GSK926 
EZH2, IC50: 0.02 μM
                   
DCE_42 
EZH2, IC50: 22.6 μM